Standard Practice for Validation of Automated Membrane Microscopy Test Methods for the Counting and Sizing of Particulate Matter Present in Parenteral Pharmaceutical Manufacturing Processes and Final Drug Products

Standard [CURRENT]

ASTM E 3411:2024

Standard Practice for Validation of Automated Membrane Microscopy Test Methods for the Counting and Sizing of Particulate Matter Present in Parenteral Pharmaceutical Manufacturing Processes and Final Drug Products

Publication date
2024
Original language
English
Pages
10

from 77.00 EUR VAT included

from 71.96 EUR VAT excluded

Format and language options

PDF download 1
  • 77.00 EUR

Shipment (3-5 working days)
  • 85.70 EUR

Monitor with the Standards Ticker

This option is only available after login.
1

Document with DRM – more on DRM

Easily subscribe: Save time and money now!

You can also subscribe to this document - together with other important standards in your industry. This makes your work easier and pays for itself after a short time.

Sparschwein_data
Subscription advantages
Sparschwein Vorteil 1_data

Important standards for your industry, regularly updated

Sparschwein Vorteil 2_data

Much cheaper than buying individually

Sparschwein Vorteil 3_data

Useful functions: Filters, version comparison and more

Publication date
2024
Original language
English
Pages
10
DOI
https://dx.doi.org/10.1520/E3411-24

Quick delivery via download or delivery service

Buy securely with a credit card or pay upon receipt of invoice

All transactions are encrypted

Short description

1.1 This practice covers the requirements for validation of test methods that apply automated membrane microscopy (AMM) to the measurement of extraneous solid insoluble particulate matter present in parenteral pharmaceutical manufacturing processes and drug products. For extensive guidance on the development of AMM test methods see Guide E3425 . 1.2 In an AMM test method, a test liquid containing suspended particles is filtered through a membrane filter, the particles are retained on the surface of the membrane filter, the membrane filter surface is imaged with an optical microscope and digital camera, and application of image analysis software determines particle count and particle sizes. 1.3 AMM test methods may be applied to the measurement of the commonly defined size categories of subvisible (<100 µm) or visible ( ≥ 100 µm) or both particulate matter present during any stage of the manufacturing of parenteral pharmaceuticals. 1.4 The test liquid characterized by an AMM test method may be a process fluid, drug substance or drug product, or liquid extracts from the surfaces of processing equipment, drug containers, delivery devices, and components thereof. 1.5 This practice does not apply to the characterization of particles inherent to parenteral suspensions (for example, cells, protein aggregates, or vaccine adjuvants) or the characterization of liquid droplets (for example, silicone oil). 1.6 Units- The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard. 1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use. 1.8 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

ICS

19.120

DOI

https://dx.doi.org/10.1520/E3411-24
Also available in
Loading recommended items...
Loading recommended items...
Loading recommended items...